A new system of vagus nerve stimulation (VNS) therapy was implanted in the first patient with drug-resistant epilepsy, as part of a global registry launched by LivaNova to evaluate the treatment in a real-world setting.
The CORE-VNS registry plans to include up to 2,000 patients with drug-resistant epilepsy to be treated with any approved VNS therapy. It will gather five years of follow-up data in up to 80 sites globally, representing one of the largest data sets in the world for drug-resistant epilepsy patients treated with VNS therapy. Patient recruitment is ongoing.
CORE-VNS will assess the VNS therapy’s safety, effectiveness, and clinical outcomes, such as seizure frequency and severity, quality of life, sleep quality, anti-epileptic therapy use, as well as seizure-related emergency department visits and hospitalizations.